Market Research Logo

North America Diabetes Drugs Market Forecast 2018-2026

1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Rising Prevalence Of Type 2 Diabetes
3.2.2. Insulin Market Is Anticipated To Generate The Highest Revenue
4. Market Dynamics
4.1. Etymology Of Diabetes Drugs Market
4.2. Market Definition And Scope
4.3. Legal, Policy And Regulatory Issues
4.4. Market Drivers
4.4.1. Increase In Prevalence Of Diabetes
4.4.2. Advances In Insulin Technology
4.4.3. Growing Elderly Population
4.5. Market Restraints
4.5.1. Stringent Regulatory Conditions And Guidelines For Biosimilar Drugs
4.5.2. Lack Of Awareness Among People
4.5.3. Cost Sensitivity Issues
4.6. Market Opportunities
4.6.1. Development Of New Formulations
4.6.2. Increasing Research And Development
4.7. Market Challenges
4.7.1. Fierce Market Competition
4.7.2. Rising Concerns In Scientific Community
4.7.3. Gaps In National-level Diabetes Management Plans
4.7.4. Poor Storage Conditions And Distribution Policies For Insulin
5. Market By Diabetes Type
5.1. Type 1
5.2. Type 2
6. Market By Product Class
6.1. Insulin
6.1.1. Fast Acting Insulin
6.1.2. Intermediate Acting Insulin
6.1.3. Long-acting Insulin
6.2. Non Insulin
6.2.1. Dpp-4 Inhibitor
6.2.2. Glp-1 Receptors Agonists
6.2.3. Sglt-2 Inhibitors
6.2.4. Others
7. Key Analytics
7.1. Porter’s Five Force Model
7.1.1. Threat Of New Entrants
7.1.2. Threat Of Substitute
7.1.3. Bargaining Power Of Suppliers
7.1.4. Bargaining Power Of Buyers
7.1.5. Threat Of Competitive Rivalry
7.2. Opportunity Matrix
7.3. Vendor Landscape
7.4. Pipeline Analysis
7.5. Key Buying Criteria
7.5.1. Safety And Efficacy
7.5.2. Availability
7.5.3. Long Term Relief
7.5.4. Affordability And Cost-effectiveness
7.5.5. Reimbursement Of Prescription Drugs
8. Geographical Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
9. Company Profiles
9.1. Eli Lilly And Company
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Swot Analysis
9.1.4. Strategic Initiatives
9.2. Astrazeneca Plc.
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Swot Analysis
9.2.4. Strategic Initiatives
9.3. B.Braun Melsungen Ag
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Swot Analysis
9.3.4. Strategic Initiatives
9.4. Novo Nordisk A/S
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Swot Analysis
9.4.4. Strategic Initiatives
9.5. Sanofi
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Swot Analysis
9.5.4. Strategic Initiatives
9.6. Diavacs, Inc.
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Swot Analysis
9.7. Xoma Corp.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Swot Analysis
9.7.4. Strategic Initiatives
9.8. Albireo Pharma Inc.
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Swot Analysis
9.9. Macrogenics, Inc.
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Swot Analysis
9.10. Astellas Pharma
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Swot Analysis
9.10.4. Strategic Initiatives
9.11. Glaxosmithkline
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Swot Analysis
9.12. Merck
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Swot Analysis
9.12.4. Strategic Initiatives
9.13. Pfizer
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Swot Analysis
9.13.4. Strategic Initiatives
9.14. Xeris Pharmaceuticals
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Swot Analysis
9.14.4. Strategic Initiatives
List Of Tables
Table 1: North America Diabetes Drugs Market, By Geography, 2018-2026 (In $ Billion)
Table 2: Regulatory Framework In Diabetes Drugs Market
Table 3: North America Diabetes Drugs Market, By Diabetes Types, 2018-2026, (In $ Billion)
Table 4: North America Diabetes Drugs Market, By Type 1 Diabetes, 2018-2026 (In $ Billions)
Table 5: North America Diabetes Drugs Market, By Type 2 Diabetes, 2018-2026 (In $ Billions)
Table 6: North America Diabetes Drugs Market, By Product Class, 2018-2026 (In $ Billions)
Table 7: North America Diabetes Drugs Market, By Insulin Type, 2018-2026, (In $ Billion)
Table 8: North America Diabetes Drugs Market, By Non Insulin Drugs, 2018-2026 (In $ Billion)
Table 9: Opportunity Matrix For Diabetes Drugs Market
Table 10: Vendor Landscape Of Diabetes Drugs Market
Table 11: Pipeline Portfolio Of Diabetes Drugs Market
Table 12: North America Diabetes Drugs Market, By Geography, 2018-2026, (In $ Billion)
Table 13: North America Diabetes Drugs Market, By Country, 2018-2026 (In $ Billion)
List Of Figures
Figure 1: North America Diabetes Drugs Market 2018-2026 (In $ Billion)
Figure 2: North America Diabetes Drugs Market, 2018-2026 (In $ Billion)
Figure 3: North America Diabetes Drugs Market, By Type 2 Diabetes, 2018-2026 (In $ Billion)
Figure 4: North America Diabetes Drugs Market, By Insulin, 2018-2026 (In $ Billion)
Figure 5: Average Life Expectancy At Birth In 2017, By Continent And Gender (In Years)
Figure 6: North America Diabetes Drugs Market, By Diabetes Type, 2017 & 2026 (In %)
Figure 7: North America Diabetes Drugs Market, By Type 1 Diabetes, 2018-2026 (In $ Billion)
Figure 8: North America Diabetes Drugs Market, By Type 2 Diabetes, 2018-2026 (In $ Billion)
Figure 9: North America Diabetes Drugs Market, By Product Class, 2018-2026 (In $ Billion)
Figure 10: North America Diabetes Drugs Market, By Insulin, 2018-2026 (In $ Billion)
Figure 11: North America Diabetes Drugs Market, By Fast Acting Insulin, 2018-2026 (In $ Billion)
Figure 12: North America Diabetes Drugs Market, By Intermediate Acting Insulin, 2018-2026 (In $ Billion)
Figure 13: North America Diabetes Drugs Market, By Long Acting Insulin, 2018-2026 (In $ Billion)
Figure 14: North America Diabetes Drugs Market, By Non-insulin, 2018-2026 (In $ Billion)
Figure 15: North America Diabetes Drugs Market, By Dpp-4 Inhibitor, 2018-2026 (In $ Billion)
Figure 16: North America Diabetes Drugs Market, By Glp-1 Receptors Agonists, 2018-2026 (In $ Billion)
Figure 17: North America Diabetes Drugs Market, By Sglt-2 Inhibitors, 2018-2026 (In $ Billion)
Figure 18: North America Diabetes Drugs Market, By Other Non Insulin Drugs, 2018-2026 (In $ Billion)
Figure 19: Porter’s Five Force Model Of Diabetes Drugs Market
Figure 20: Key Buying Impact Analysis
Figure 21: North America Diabetes Drugs Market, Regional Outlook, 2017 & 2026 (In %)
Figure 22: North America Diabetes Drugs Market, 2017 & 2026 (In %)
Figure 23: United States Diabetes Drugs Market, 2018-2026 (In $ Billion)
Figure 24: Canada Diabetes Drugs Market, 2018-2026 (In $ Billion)

North America Diabetes Drugs Market Forecast 2018-2026

KEY FINDINGS

North America is the world’s largest market for diabetes drugs and holds more than half of total market volume. The market is expected to exhibit a CAGR of 4.97% over the forecast years of 2018-2026

MARKET INSIGHTS

In North America, the US market holds the maximum share in the use of diabetes drugs. Growing diabetic population is responsible for driving growth in this market. Also, rising government initiatives and investments for diabetes drugs in the healthcare sector is boosting growth in this region. However, stringent regulatory conditions and guidelines for biosimilar drugs and cost sensitivity issues are some of the challenges faced by this market. Another significant market in this region is Canada. The market is expected to evolve with the highest CAGR by the end of the forecast period.

COMPETITIVE INSIGHTS

Big-league players like Astellas Pharma, Eli Lilly And Company, Novo Nordisk A/S, GlaxoSmithKline, Macrogenics Inc, AstraZeneca Plc, Sanofi, Albireo Pharma Inc, Pfizer, Xoma Corp and B.Braun Melsungen Ag are competing in this market.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;